Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Wilson

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
The Lancet. Psychiatry|June 17, 2026
Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologiesWayne Hall, Tesfa M Yimer, Rachel Lees Thorne, et al.
BMJ Open|July 15, 2020
Australian treatment outcome study: protocol for the 18-20-year follow-up of a prospective longitudinal cohort examining the natural history of heroin dependence and associated mortality, psychiatric and physical health, and health service useChristina Marel, Katherine Mills, Rachel Visontay, et al.
International Journal of Mental Health and Addiction|January 23, 2023
Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence: Key Findings from the 18-20-Year Follow-Up of the Australian Treatment Outcome Study (ATOS)Christina Marel, Jack Wilson, Shane Darke, et al.
Drug and Alcohol Review|March 9, 2026
Prevalence, Associations and Comorbidity of Cannabis Use and Cannabis Use Disorders in the Australian National Mental Health Surveys From 2007 to 2020-22Jack Wilson, Matthew Sunderland, Siobhan O'Dean, et al.
ACS Bio & Med Chem Au|October 25, 2022
Plant Cysteine Oxidase Oxygen-Sensing Function Is Conserved in Early Land Plants and AlgaeLeah J Taylor-Kearney, Samuel Madden, Jack Wilson, et al.
The International Journal on Drug Policy|September 6, 2025
Media representation of methamphetamine-related deaths: Exploring links to public stigma and support for harm reductionSteph Kershaw, Jessica Deng, Georgette Borel, et al.
Addiction (Abingdon, England)|October 11, 2023
Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over studyDominic Oliver, Amir Englund, Edward Chesney, et al.
The Lancet. Psychiatry|March 19, 2026
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysisJack Wilson, Olivia Dobson, Andrew Langcake, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 15, 2022
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratiosAmir Englund, Dominic Oliver, Edward Chesney, et al.
Cannabis and Cannabinoid Research|December 9, 2022
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover StudyLucy A Chester, Amir Englund, Edward Chesney, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
The Lancet. Psychiatry|June 17, 2026
Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologiesWayne Hall, Tesfa M Yimer, Rachel Lees Thorne, et al.
BMJ Open|July 15, 2020
Australian treatment outcome study: protocol for the 18-20-year follow-up of a prospective longitudinal cohort examining the natural history of heroin dependence and associated mortality, psychiatric and physical health, and health service useChristina Marel, Katherine Mills, Rachel Visontay, et al.
International Journal of Mental Health and Addiction|January 23, 2023
Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence: Key Findings from the 18-20-Year Follow-Up of the Australian Treatment Outcome Study (ATOS)Christina Marel, Jack Wilson, Shane Darke, et al.
Drug and Alcohol Review|March 9, 2026
Prevalence, Associations and Comorbidity of Cannabis Use and Cannabis Use Disorders in the Australian National Mental Health Surveys From 2007 to 2020-22Jack Wilson, Matthew Sunderland, Siobhan O'Dean, et al.
ACS Bio & Med Chem Au|October 25, 2022
Plant Cysteine Oxidase Oxygen-Sensing Function Is Conserved in Early Land Plants and AlgaeLeah J Taylor-Kearney, Samuel Madden, Jack Wilson, et al.
The International Journal on Drug Policy|September 6, 2025
Media representation of methamphetamine-related deaths: Exploring links to public stigma and support for harm reductionSteph Kershaw, Jessica Deng, Georgette Borel, et al.
Addiction (Abingdon, England)|October 11, 2023
Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over studyDominic Oliver, Amir Englund, Edward Chesney, et al.
The Lancet. Psychiatry|March 19, 2026
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysisJack Wilson, Olivia Dobson, Andrew Langcake, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 15, 2022
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratiosAmir Englund, Dominic Oliver, Edward Chesney, et al.
Cannabis and Cannabinoid Research|December 9, 2022
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover StudyLucy A Chester, Amir Englund, Edward Chesney, et al.
Pageof 6